FeesSafety
Pluang+

RTX raises 2026 outlook after strong Q3 sales and earnings growth

Company Fundamentals
20 Oct 2026, 17:14 WIB
Proactive Investors
View Source
Bullish
RTX raises 2026 outlook after strong Q3 sales and earnings growth

RTX Corp reported an 11% increase in third-quarter sales to $25 billion and a 33% rise in adjusted earnings per share to $2.26. The company raised its 2026 sales forecast to $97-$97.5 billion and adjusted EPS guidance to $7.65-$7.75, citing strong demand in aerospace and defense segments. Despite a drop in operating cash flow, RTX ended the quarter with a record $340 billion backlog and plans to focus on production growth and technology investment. Shares rose about 2.3% following the update.

RTX Corp's outlook update comes as a backdrop to Industrials-sector activity on Pluang. For readers following this sector, as of Oct 20, 2026 19:43 WIB, 52 of 135 priced US Industrials stocks rose while 78 fell. Notable movers include GE Aerospace at USD 299.00 with a 3.95% decline and C.H. Robinson Worldwide, Inc. at USD 144.20 with a 3.85% gain.

More News

SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

SI-BONE Q3 revenue rises 15% to $55.7M; new Onyx device expands market to $5B

SI-BONE reported a 15% increase in third-quarter 2026 revenue to $55.7 million, driven by growing adoption of its surgical implants. The launch of the iFuse Granite Onyx device, approved by the FDA, expands the company's addressable market to $5 bill...

Company Fundamentals
Bullish
8 minutes ago
Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell report strong AI-driven growth despite recent stock drops.

Nvidia, Coherent, and Dell Technologies all supply key components for AI infrastructure and have reported strong revenue growth despite significant stock price declines. Nvidia's data center revenue rose 21% sequentially, with a fiscal Q4 revenue for...

Bullish
22 minutes ago
BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio's Attruby revenue soars 134% YoY; FDA decision for BBP-418 due Nov 27

BridgeBio reported a 134% year-over-year increase in net product revenue for Attruby, reaching $253.2 million in Q3 2026, driven by new patients starting treatment for transthyretin amyloid cardiomyopathy. The company anticipates an FDA decision on N...

Company Fundamentals
Bullish
50 minutes ago
Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria raises dividends for 57 years but faces declining cigarette sales and high payout risks.

Altria Group has increased its dividends for 57 consecutive years, maintaining a strong yield of 5.9%, well above the S&P 500 average. However, the company's cigarette sales volumes continue to decline, with a 2.8% drop in cigarette volume this year ...

Company Fundamentals
Neutral
51 minutes ago
Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth reported $1.03 billion in revenue for Q3 2026, surpassing company guidance. The firm sees enterprise software as the key channel for AI deployment, with strong growth in cybersecurity and risk bookings, up over 40% year-to-date due to incre...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App